American Journal of Cardiology
Volume 95, Issue 5 , Pages 558-564 , 1 March 2005

Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy

  • Christopher M. O'Connor, MD

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • Corresponding Author InformationAddress for reprints: Christopher M. O'Connor, MD, Division of Cardiology, Department of Medicine, Box 3356, Room 7401-A Duke North, Duke University Medical Center, Durham, North Carolina 27710.
    • ,
  • Steven Gottlieb, MD

      Affiliations

    • Baltimore VAMC, Baltimore, Maryland
    • ,
  • Jamieson M. Bourque, MD

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Heidi Krause-Steinrauf, MS

      Affiliations

    • National Heart, Lung, and Blood Institute, Bethesda, Maryland
    • ,
  • Inder Anand, MD

      Affiliations

    • Minneapolis VAMC, Minneapolis, Minnesota
    • ,
  • Jeffrey L. Anderson, MD

      Affiliations

    • University of Utah Health Sciences Center, Salt Lake City, Utah
    • ,
  • Jonathan F. Plehn, MD

      Affiliations

    • National Heart, Lung, and Blood Institute, Bethesda, Maryland
    • ,
  • Marc A. Silver, MD

      Affiliations

    • Advocate Christ Medical Center, Oak Lawn, Illinois
    • ,
  • Michel White, MD

      Affiliations

    • Montreal Heart Institute, Montreal, Quebec, Canada
    • ,
  • Peter Carson, MD

      Affiliations

    • Washington, DC VAMC, Washington, DC
    • ,
  • BEST Investigators

Received 6 May 2004 ,Accepted 29 October 2004.

References 

  1. Kostis JB , Wilson AC , Sanders MR , Byington RP  BHAT Study Group . Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction who receive propranolol . Am J Cardiol . 1988;61:975–978
  2. Roberts R, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction (Results of the Thrombolysis In Myocardial Infarction (TIMI) II-B Study) . Circulation . 1991;83:422–437
  3. The MIAMI Trial Research Group . Metoprolol in acute myocardial infarction (MIAMI) (A randomised placebo-controlled international trial) . Eur Heart J . 1985;6:199–226
  4. First International Study of Infarct Survival Collaborative Group . Randomised trial of intravenous atenolol among 16,207 cases of suspected acute myocardial infarction: ISIS-1 . Lancet . 1986;2:57–66
  5. Kaplan JR , Manuck SB . Antiatherogenic effects of beta-adrenergic blocking agents: theoretical, experimental, and epidemiologic considerations . Am Heart J . 1994;5:1316–1328
  6. Bondjers G . Anti-atherosclerotic effects of beta-blockers . Eur Heart J . 1994;15(suppl):C8–C15
  7. Frishman WH , Lazar EJ . Reduction of mortality, sudden death and non-fatal reinfarction with beta-adrenergic blockers in survivors of acute myocardial infarction: a new hypothesis regarding the cardioprotective action of beta-adrenergic blockade . Am J Cardiol . 1990;66(suppl):66G–70G
  8. Dargie HJ . Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial . Lancet . 2001;357:1385–1390
  9. The SOLVD Investigators . Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions . N Engl J Med . 1992;327:685–691
  10. The SOLVD Investigators . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure . N Engl J Med . 1991;325:293–302
  11. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions . Lancet . 1992;340:1173–1178
  12. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure (ATLAS Study Group) . Circulation . 1999;100:2312–2318
  13. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure . N Engl J Med . 1996;334:1349–1355
  14. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, et al  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST) . Am Heart J . 1997;134:44–54
  15. CIBIS Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). a randomised trial. Lancet 1999;353:9–13.
  16. The MERIT-HF Study Group . Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) . Lancet . 1999;353:2001–2007
  17. Cohn JN , Tognoni G  Valsartan Heart Failure Trial Investigators . A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure . N Engl J Med . 2001;345:1667–1675
  18. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al  Effect of carvedilol on survival in severe chronic heart failure . N Engl J Med . 2001;344:1651–1658
  19. The Beta-Blocker Evaluation of Survival Trial Investigators . A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure . N Engl J Med . 2001;344:1659–1667
  20. The Randomized Aldactone Evaluation Study (RALES) Investigators . Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure . Am J Cardiol . 1996;78:902–907
  21. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both . N Engl J Med . 2003;349:1893–1906
  22. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al  Effect of amlodipine on morbidity and mortality in severe chronic heart failure . N Engl J Med . 1996;335:1107–1114
  23. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patient with left ventricular dysfunction after myocardial infarction . N Engl J Med . 1995;333:1670–1676
  24. Poole-Wilson PA , Swedberg K , Cleland JG . Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial . Lancet . 2003;362:7–13
  25. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial . Lancet . 2003;362:767–771
  26. The BEST Steering Committee . Design of the Beta-Blocker Evaluation Survival Trial (BEST) . Am J Cardiol . 1995;75:1220–1223
  27. He J , Ogden LG , Bazzano LA , Vupputuri S , Loria C , Whelton PK . Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study . Arch Intern Med . 2001;161:996–1002
  28. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al  American College of Cardiology; American Heart Association (ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article: a report of the ACC/AHA task force on practice guidelines (Committee on the Management of Patients With Unstable Angina)) . J Am Coll Cardiol . 2002;40:1366–1374

 The β-Blocker Evaluation of Survival Trial was sponsored by the Division of Epidemiology and Clinical Applications of the National Heart, Lung and Blood Institute, Bethesda, Maryland and the Department of Veterans Affairs Cooperative Studies Program, Washington, DC, through an interagency agreement. Additional support was provided by Incara Pharmaceuticals Corporation, Durham, North Carolina, which also supplied bucindolol and placebo.

PII: S0002-9149(04)01770-9

doi: 10.1016/j.amjcard.2004.11.001

American Journal of Cardiology
Volume 95, Issue 5 , Pages 558-564 , 1 March 2005

Article Tools

* Image Usage & Resolution